These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9177446)

  • 1. Normal G-CSF-mobilized CD34+ peripheral blood stem cells in paroxysmal nocturnal hemoglobinuria: a perspective for autologous transplantation.
    Musto P; D'Arena G; Cascavilla N; Carotenuto M
    Leukemia; 1997 Jun; 11(6):890-2. PubMed ID: 9177446
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating primitive stem cells in paroxysmal nocturnal hemoglobinuria (PNH) are predominantly normal in phenotype but granulocyte colony-stimulating factor treatment mobilizes mainly PNH stem cells.
    Johnson RJ; Rawstron AC; Richards S; Morgan GJ; Norfolk DR; Hillmen SO
    Blood; 1998 Jun; 91(12):4504-8. PubMed ID: 9616145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and sustained allogeneic transplantation using immunoselected CD34(+)-selected peripheral blood progenitor cells mobilized by recombinant granulocyte- and granulocyte-macrophage colony-stimulating factors.
    Corringham RE; Ho AD
    Blood; 1995 Sep; 86(5):2052-4. PubMed ID: 7544651
    [No Abstract]   [Full Text] [Related]  

  • 4. [The response of bone marrow hematopoietic cells to G-CSF in paroxysmal nocturnal hemoglobinuria patients].
    Cao YR; Shao ZH; Liu H; Shi J; Bai J; Tu MF; Wang HQ; Xing LM; Cui ZZ; Sun J; Jia HR; Yang TY
    Zhonghua Xue Ye Xue Za Zhi; 2005 Apr; 26(4):235-8. PubMed ID: 15949269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of double immunomagnetic positive sorting to ex vivo expansion of marrow CD34(+)CD59(+) cells from patients with paroxysmal nocturnal hemoglobinuria].
    Xiao J; Wu YJ; Zhang ZN; Lu ZJ; Chen SP; Dong HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Apr; 11(2):179-83. PubMed ID: 12744742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of enriched CD34+ cells from healthy volunteers and those from patients treated with chemotherapy plus granulocyte colony-stimulating factor (G-CSF).
    Suzuki T; Muroi K; Tomizuka H; Amemiya Y; Miura Y
    Stem Cells; 1995 May; 13(3):273-80. PubMed ID: 7542113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
    Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
    Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
    Haas R; Murea S
    Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation.
    Kiss JE; Rybka WB; Winkelstein A; deMagalhaes-Silverman M; Lister J; D'Andrea P; Ball ED
    Bone Marrow Transplant; 1997 Feb; 19(4):303-10. PubMed ID: 9051238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
    Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
    Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
    Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
    Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor.
    Dunbar CE; Seidel NE; Doren S; Sellers S; Cline AP; Metzger ME; Agricola BA; Donahue RE; Bodine DM
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11871-6. PubMed ID: 8876230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
    Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
    Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Composition analysis of hematopoietic stem/progenitor cells in peripheral blood and bone marrow from patients with paroxysmal nocturnal hemoglobinuria].
    Han B; Wu Y; Zhang Z
    Zhonghua Xue Ye Xue Za Zhi; 2002 Feb; 23(2):73-6. PubMed ID: 12015074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine-mobilized peripheral blood CD34+Thy-1+Lin- human hematopoietic stem cells as target cells for transplantation-based gene therapy.
    Chen BP; Fraser C; Reading C; Murray L; Uchida N; Galy A; Sasaki D; Tricot G; Jagannath S; Barlogie B
    Leukemia; 1995 Oct; 9 Suppl 1():S17-25. PubMed ID: 7475307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferative status and antigenic profile of CD34+ peripheral blood progenitors mobilized by chemotherapy and G-CSF.
    Rumi C; Rutella S; Puggioni PL; Etuk B; Leone G
    Eur J Histochem; 1997; 41 Suppl 2():47-8. PubMed ID: 9859778
    [No Abstract]   [Full Text] [Related]  

  • 18. T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells.
    Rondelli D; Anasetti C; Fortuna A; Ratta M; Arpinati M; Bandini G; Lemoli RM; Tura S
    Bone Marrow Transplant; 1998 Jun; 21(12):1183-91. PubMed ID: 9674849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of surface markers on CD34+ cells, isolated from cord blood and G-CSF primed peripheral blood.
    Barbosa IL; de Sousa ME; Godinho MI; Teixeira AM; Carvalhais A
    Bone Marrow Transplant; 1998 Jul; 22 Suppl 1():S56. PubMed ID: 9715889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
    Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
    Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.